PROTALIX BIOTHERAPEUTICS INC
NYSE: PLX (Protalix BioTherapeutics, Inc.)
Kemas kini terakhir: 22 jam lalu2.39
-0.21 (-8.08%)
| Penutupan Terdahulu | 2.60 |
| Buka | 2.57 |
| Jumlah Dagangan | 837,831 |
| Purata Dagangan (3B) | 686,643 |
| Modal Pasaran | 186,497,920 |
| Harga / Pendapatan (P/E TTM) | 59.75 |
| Harga / Pendapatan (P/E Ke hadapan) | 8.35 |
| Harga / Jualan (P/S) | 3.93 |
| Harga / Buku (P/B) | 4.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 - 12 May 2025 |
| Margin Keuntungan | 5.49% |
| Margin Operasi (TTM) | 39.57% |
| EPS Cair (TTM) | 0.040 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 73.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.79% |
| Nisbah Semasa (MRQ) | 2.35 |
| Aliran Tunai Operasi (OCF TTM) | 8.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 5.43 M |
| Pulangan Atas Aset (ROA TTM) | 3.10% |
| Pulangan Atas Ekuiti (ROE TTM) | 7.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Protalix BioTherapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.13 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 13.70% |
| % Dimiliki oleh Institusi | 6.03% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Point72 Asia (Singapore) Pte. Ltd. | 30 Sep 2024 | 47,073 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Mar 2025 | Pengumuman | Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 |
| 17 Mar 2025 | Pengumuman | Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results |
| 10 Mar 2025 | Pengumuman | Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 |
| 04 Feb 2025 | Pengumuman | Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |